The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care

Jan 2, 2026Cureus

How GLP-1 Agonists May Affect Treatment of Autoimmune Thyroid Disease

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Autoimmune thyroid disease (AITD) is the most prevalent organ-specific autoimmunity, affecting thyroid function globally.

AITD often coexists with metabolic disorders, indicating a potential link between immune dysregulation and metabolic health.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown benefits for type 2 diabetes and obesity, including weight reduction and improved insulin sensitivity.
Preliminary reports suggest that GLP-1RAs may influence thyroid volume, thyroid function, and autoimmune activity in patients with AITD.
Mechanistic hypotheses propose that GLP-1RAs could reduce specific immune cell activity and improve balance of signaling molecules related to metabolism.
Safety concerns exist regarding potential risks associated with thyroid C-cell tumors and the need for careful management of thyroid hormone therapy.

AI simplified

Autoimmune thyroid disease (AITD), including Hashimoto thyroiditis and Graves' disease, represents the most prevalent organ-specific autoimmunity and a major cause of thyroid dysfunction worldwide. Increasingly, AITD coexists with metabolic disorders such as obesity, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting an interplay between immune dysregulation and metabolic health. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes. Beyond these metabolic benefits, accumulating evidence indicates that GLP-1RAs exert immunomodulatory effects, including suppression of pro-inflammatory cytokines, enhancement of regulatory T-cell function, and improvements in adipose tissue and gut-derived immune signaling. Although dedicated trials of GLP-1RAs in AITD are lacking, preliminary reports suggest potential impact on thyroid volume, thyroid function, and autoimmune activity. Mechanistic hypotheses include reduced leptin-driven T-helper (Th)1/Th17 activity, improved adipokine balance, and modulation of gut-thyroid axis pathways. Potential benefits must be weighed against safety considerations, including theoretical risks of thyroid C-cell tumors from animal studies and the need for careful adjustment of thyroid hormone therapy in patients experiencing significant weight loss. This review synthesizes the current understanding of AITD pathophysiology, summarizes emerging evidence on the immunometabolic effects of GLP-1RAs, and explores potential therapeutic implications for patients with concurrent thyroid autoimmunity and metabolic disease. Rigorous clinical and translational studies are needed to clarify the role of GLP-1RAs in the management of AITD.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief